Posts

BMS CEO Boerner Says No Compulsion to Chase Deals Despite Quiet M&A Year

on

RA Capital Launches Rare Disease Company Oak Hill Bio onto Nasdaq via SPAC

on

Mid-Year Healthcare Venture Trends to Watch in 2026

on

The Golden Triangle and the gaps: Rethinking UK biotech – recent industry dialogue and policy context

on

uniQure Announces Pricing of Upsized $225 Million Public Offering: Details and Highlights

on

RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea – 2026 update

on

Ethyreal Bio emerges with $101M to challenge Amgen’s Tepezza in thyroid eye disease

on

Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027

on

Full-Life Technologies Raises $150M to Accelerate Clinical Assets and Manufacturing

on

Recordati Confirms Non-Binding €10.9 Billion Full Takeover Offer from CVC Capital Partners

on

Biopharma Sentiment Index Q1 2026: Positive Outlook Amid Rally and Challenges

on

Immunovant Announces Pricing of $550 Million Common Stock Financing

on

Expert Insights to Navigate Your CGT Challenges: Recent Updates and Strategic Guidance for 2025

on

Langers Team Launch $77.5M Fund to Invest at Intersection of Technology and Biology

on

Amgen to Invest Over $600M in New Innovation Centre at California Headquarters

on

Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders

on

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

on

Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M

on

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

on

Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer

on